Leuprolide acetate and central retinal vein occlusion

Area of Science:

• Ophthalmology
• Oncology
• Vascular Medicine

Background:

• Central retinal vein occlusion (CRVO) is a serious vascular condition affecting vision.
• Leuprolide acetate is a gonadotropin-releasing hormone agonist used for prostate cancer treatment.
• Thromboembolic events are known potential side effects of leuprolide acetate therapy.

Observation:

• A 63-year-old man with prostate cancer experienced CRVO two months after initiating leuprolide acetate.
• The patient had controlled hypertension and mild hypercholesterolemia, suggesting these were not primary drivers of the event.
• Despite management of risk factors, the CRVO progressed.

Findings:

• The temporal association between leuprolide acetate initiation and CRVO suggests a possible causal link.
• Leuprolide acetate's known association with thromboembolic events and disseminated intravascular coagulation supports its potential role.
• This case highlights a potential, albeit rare, ocular complication of leuprolide acetate therapy.

Implications:

• Further investigation into the thrombogenic potential of leuprolide acetate in ocular circulation is warranted.
• Ophthalmologists and oncologists should be aware of this potential adverse event.
• Consideration of alternative treatments or closer ocular monitoring may be necessary for patients on leuprolide acetate with risk factors.